ClinicalTrials.gg
CompletedNCT06924385Updated Apr 13, 2026

Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

A Phase 1 interventional study of Telpegfilgrastim Injection and Telpegfilgrastim Injection in Preeclampsia, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies in Pre-Eclampsia with a site in China — 12 open to participants now, 13 under way, 2 of them phase 3. Pre-Eclampsia · China.

Enrollment
17th of 19
18 · median 180
Started
2025
with 3 others
Phase 1
3 of 36
1 open now
Registered
33rd of 36
by date
Lead sponsor
2 of 36
Xiamen Amoytop Biotech Co., Ltd.

Among the 36 studies in Pre-Eclampsia with a site in China, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 in phase 1, and was the 33rd registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 244 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

12 of the 36 studies in Pre-Eclampsia with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 161 Pre-Eclampsia studies recruiting now, 80 (50%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Pre-Eclampsia with a site in China, or all of them as a file.
02

Study summary

This is an open-label, single-arm, Phase Ⅰa clinical study designed to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of multiple doses of Telpegfilgrastim Injection in non-pregnant women of childbearing. It contains two cohorts: Cohort 1, healthy childbearing-age non-pregnant participants, and Cohort 2, childbearing-age non-pregnant participants with a history of preeclampsia, totaling 30 non-pregnant women of childbearing age will be enrolled.

Each participant in Cohort 2 will go through a screening period, a baseline phase (the day before the first dose), a treatment period, and a follow-up period after dosing.

03

Conditions studied

  • Preeclampsia

Browse trials for

Keywords

  • PEG-rhG-CSF
  • Telpegfilgrastim Injection
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants are able to understand and comply with the contents, requirements, and restrictions of the protocol, complete the study as required by the protocol, and are fully aware of the possible adverse reactions, and voluntarily sign the form before the trial.
  2. Female, aged between 18 and 45 years old (inclusive of 18 and 45 years old).
  3. (BMI) ≥18.5 and \<28.0 kg/m\^2, weight ≥45 kg.
  4. Healthy, childbearing-age, non-pregnant women: At the screening visit and before the first dose administration, a comprehensive physical examination is conducted, including general physical examination, vital signs (pulse between 50 and 100 bpm at rest, systolic blood pressure between 90 and 139 mmHg, diastolic blood pressure between 50 and 89 mmHg, inclusive of the critical values), as well as laboratory tests [blood routine, blood biochemistry, coagulation function, thyroid function (FT3, FT4, TSH), urine routine, etc.] and auxiliary examinations (anteroposterior chest X-ray, 12-lead , ultrasonography) showing all parameters normal or abnormal but without clinical significance.
  5. Willing to participate in the planned PK blood sampling studies and able to comply with the medication and blood sample collection procedures.
  6. Negative blood pregnancy test within 24 hours before the first dose administration, and the participant must agree to use effective measures during the study period and for 6 months after medication. The participant must agree to use at least one of the following contraceptive methods: condom; subcutaneous contraceptive implant; intrauterine device or intrauterine system; high-efficiency oral contraceptives, with or without progestin; injectable progestin; contraceptive vaginal ring; transdermal contraceptive patch.
  7. Women of childbearing age with a history of preeclampsia: A documented history of pulmonary embolism (PE), requiring confirmation of the diagnosis through prior hospitalization medical records.

Exclusion criteria

Exclusion Criteria:

  1. Healthy, childbearing-age, non-pregnant women: Those with organic lesions in vital organs such as the heart, liver, kidneys, brain, and lungs; a clear history of diseases or other significant conditions affecting the central nervous system, cardiovascular system, cerebrovascular, hematological system, urinary system, digestive system, respiratory system, metabolic and musculoskeletal system; a history of diseases; a history of endocrine disorders, such as thyroid dysfunction.
  2. Healthy, childbearing-age, non-pregnant women: Those with gastrointestinal, liver, kidney, or other known diseases that interfere with drug absorption, distribution, metabolism, or excretion.
  3. Suffering from malignant tumors or any history of any within 5 years prior to screening (except for completely resected carcinoma in situ of the cervix, non- cutaneous squamous cell carcinoma, or basal cell carcinoma).
  4. History of organ transplantation or use of agents within in the past 3 months or planned use, including but not limited to; calcineurin inhibitors such as tacrolimus and cyclosporine; mycophenolate agents such as mycophenolate mofetil and mycophenolate sodium enteric-coated tablets; medications such as prednisone and methylprednisolone; others such as sirolimus, azathioprine, mizoribine and leflunomide;
  5. A history of poorly controlled psychiatric disorders with medication.
  6. Current or history of severe or persistent infection within the past 3 months (requiring hospitalization or opportunistic infections); or evidence of active and uncontrolled viral infections, such as , (HBsAg positive), (anti-HCV antibody positive), syphilis, or any bacterial, parasitic, or fungal infection requiring treatment.
  7. Allergy to rhG-CSF products (including rhG-CSF and PEG-modified rhG-CSF) and their components, or allergy to recombinant human proteins or polypeptide drugs derived from E. coli.
  8. Use of human granulocyte colony-stimulating factor (G-CSF) therapies within the past 3 months prior to screening; planned or current use of drugs with potential drug interactions with G-CSF therapies, such as lithium;
  9. Use of any prescription or over-the-counter drugs (including traditional Chinese medicine, health supplements, etc.) within 14 days before the first dose of the test drug or during the drug's 5 half-lives (whichever is longer), unless both the researcher and the sponsor agree that it has no impact on the clinical study.
  10. Current or planned use of aspirin, statins, and/or any other drugs that affecting the pathogenesis of preeclampsia (including but not limited to low molecular weight heparin, broccoli sprout extract tablets, digoxin immune Fab, recombinant antithrombin III, proton pump inhibitors, metformin, etc.);
  11. Vaccination with live or attenuated vaccines within 3 months before the start of the trial.
  12. History of drug abuse, drug use, or alcoholism (drug abuse history or use of narcotics in the past five years; consumption of 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
  13. Smoking (or use of tobacco products) in the past 3 months, or those who do not agree to refrain from smoking during the study period.
  14. Participation in a clinical drug trial within 3 months before screening or 5 times the drug's half-life as specified in other trial drug package inserts/investigator brochures/ forms (whichever is longer), or other conditions deemed unsuitable for enrollment by the researcher.
  15. Women of childbearing age with a history of preeclampsia: A history/current blood system disease (myelodysplastic syndrome, thalassemia, sickle cell anemia, hemolytic anemia, hemophilia, and/or bleeding disorders).
  16. Women of childbearing age with a history of preeclampsia: Congestive heart failure ( class II\~IV), myocardial infarction, unstable angina, and/or severe heart disease in the past or present within 6 months before enrollment.
  17. Women of childbearing age with a history of preeclampsia: Severe cerebrovascular disease within 6 months before enrollment.
  18. Women of childbearing age with a history of preeclampsia: Evaluation by the investigator at the time of screening for significant lung disease.
  19. Women of childbearing age with a history of preeclampsia: Severe hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg) or uncontrolled hypertension after antihypertensive medication treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥90 mmHg) or malignant hypertension, hypertensive emergency, hypertensive urgency, etc.
  20. Women of childbearing age with a history of preeclampsia: Severe or malignant retinopathy. Severe lesions are defined as retinal hemorrhage, microaneurysms, cotton-wool spots, hard exudates, or a combination thereof. Malignant lesions are defined as severe retinopathy combined with optic disc edema.
  21. Women of childbearing age with a history of preeclampsia: Poorly controlled diabetes, poorly controlled thyroid disease with medication.
  22. Women of childbearing age with a history of preeclampsia: Severe liver disease or liver dysfunction ( or AST >2×), renal impairment, creatinine (Cr) >1.5×ULN.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1:telpegfilgrastim Injection low dose group

    Drug: Telpegfilgrastim Injection

  • Experimental
    Cohort 1:telpegfilgrastim Injection middle dose group

    Drug: Telpegfilgrastim Injection

  • Experimental
    Cohort 1:telpegfilgrastim Injection high dose group

    Drug: Telpegfilgrastim Injection

  • Experimental
    Cohort 2:telpegfilgrastim Injection low dose group

    Drug: Telpegfilgrastim Injection

  • Experimental
    Cohort 2:telpegfilgrastim Injection high dose group

    Drug: Telpegfilgrastim Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event(AE).

    Time frame: Week1-6.

  2. respiration.

    Time frame: Week1-6.

  3. body temperature.

    Time frame: Week1-6.

  4. Number of participants with clinically significant change from baseline in physical examination.

    Time frame: Week1-6.

  5. Number of participants with clinically significant change from baseline in laboratory test.

    Time frame: Week1-6.

  6. Electrocardiogram.

    Time frame: Week1-6.

  7. Anti-drug antibody.

    Time frame: week1-6.

  8. Area under the plasma drug concentration-time curve, AUC 0-t.

    Time frame: Day36.

  9. Area Under the Concentration-Time Curve from time 0 to time tau,AUC 0-tau.

    Time frame: Day36.

  10. Area under the plasma drug concentration-time curve from time 0 to infinity, AUC 0-∞.

    Time frame: Day36.

  11. Maximum concentration (Cmax)

    Time frame: Day36.

  12. Time to maximum concentration(Tmax)

    Time frame: Day36.

  13. Drug half-life (t1/2)

    Time frame: Day36.

  14. Steady-state peak concentration (Css_max)

    Time frame: Day36.

  15. Steady-state trough concentration (Css_min)

    Time frame: Day36.

  16. Steady-state average concentration (Css_avg)

    Time frame: Day36.

  17. Apparent clearance (CL/F)

    Time frame: Day36.

  18. Apparent volume of distribution (Vd/F)

    Time frame: Day36.

  19. Fluctuation index (DF)

    Time frame: Day36.

  20. Accumulation ratio at steady state (Rss)

    Time frame: Day36.

Secondary outcomes

  1. VEGF(Vascular Endothelial Growth Factor)

    Time frame: Day 36

  2. IL-4(Interleukin-4)

    Time frame: Day 36

  3. IL-6(Interleukin-)

    Time frame: Day 36

  4. IL-10(Interleukin-10)

    Time frame: Day 36

  5. TNF-α(Tumor Necrosis Factor-α)

    Time frame: Day 36

  6. TGF-β(Transforming Growth Factor-β)

    Time frame: Day 36

  7. Th17/Treg cell ratio

    Time frame: Day 36

  8. CD34+ cell level

    Time frame: Day 36

07

Study locations

1 site
  • Peking University Third Hospital
    Beijin, Beijing Municipality 100191, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jan 2026, 9 months.

Of 20 phase 1 interventional studies under Pre-Eclampsia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 11, 2025
StartActual
Apr 6, 2025
Primary completionActual
Jan 20, 2026
CompletionActual
Jan 20, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06924385
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Apr 6, 2025
Primary completion
Jan 20, 2026
Completion
Jan 20, 2026
Last update
Apr 13, 2026

Study contacts

Yuan Wei, Ph.D
principal investigator · Peking University Third Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telpegfilgrastim

Start the discussion